AFP and neoplasm: Among all patients, nine (75%) did not develop tumor recurrence up to 24 weeks and displayed stronger IFN-γ-producing CTL responses against AFP, MAGE-1, and/or GPC-3 antigens than the others who developed recurrence after vaccination.